Small nucleolar RNA host gene 22 (non-protein coding) (SNHG22)

Small nucleolar RNA host gene 22 (SNHG22) is a long non-coding RNA that acts as a molecular scaffold and competing endogenous RNA (ceRNA) in several forms of cancer[1][2]. SNHG22 promotes tumor cell proliferation, migration, and invasion primarily by acting as a sponge for tumor-suppressive microRNAs (such as miR-200c-3p[1], miR-128-3p[2], and miR-4492[3]), thereby derepressing oncogenic targets including Notch1[1], E2F3[2], and others. In the nucleus, SNHG22 interacts with the histone methyltransferase EZH2, recruiting it to the promoters of tumor suppressor genes, leading to epigenetic silencing via increased H3K27 trimethylation[1]. SNHG22 is consistently found at elevated levels in various cancer tissues, where it facilitates disease progression and, consequently, is proposed as a prognostic biomarker and a potential therapeutic target[1][2][4]. Although there are no specific drugs directly targeting SNHG22 currently known, its role in oncogenesis makes it an emerging focus for RNA-targeted therapies and clinical biomarker development.

Other names

SCARNA17HGU91mgU12-22/U4-8SCARNA17small nucleolar RNA host gene 22 (non-protein coding)SNHG22